trending Market Intelligence /marketintelligence/en/news-insights/trending/or8klzzqc9ttuhlidmzrkq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie rheumatoid arthritis drug delivers more improvements in phase 3 trials

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AbbVie rheumatoid arthritis drug delivers more improvements in phase 3 trials

AbbVie Inc. said patients treated with its investigational rheumatoid arthritis drug upadacitinib showed additional improvements, based on new data from three phase 3 trials.

The three studies, called Select-Next, Select-Beyond and Select-Monotherapy, evaluated the drug in adults with moderate to severe rheumatoid arthritis.

Patients in Select-Next reported improvements in physical function, joint pain and morning stiffness as early as one week after first receiving upadacitinib, compared to placebo.

In Select-Beyond, which also used placebo as a comparison, the upadacitinib group said physical function and joint pain improved after two weeks, while morning stiffness improved after one week.

Upadacitinib, in as early as two weeks, delivered clinically meaningful quality of life improvements to patients in Select-Monotherapy. Patients treated with anti-rheumatic drug methotrexate improved, in terms of physical function, only after eight weeks, and in terms of pain and morning stiffness, only after four weeks. AbbVie said additional data from Select-Monotherapy will be presented at a future medical meeting.

North Chicago, Ill.-based AbbVie is evaluating upadacitinib, which has yet to secure regulatory approval, across six studies in its Select clinical trial program.

Rhematoid arthritis is a disease that affects about 1.5 million people in the U.S. and happens when the body's immune system mistakenly attacks the joints, causing inflammation, swelling and pain.